If you’d invested in: Bango and Vernalis

Bango creates technology that enables payments to be made via mobile phones. while Vernalis develops drugs.

If only


Cambridge-based Bango (Aim: BGO) develops technology that enables payments to be made via mobile phones. Bango collects a fee on each transaction made. Revenue was up by 200% in the year to 31 December, with strong growth predicted this year too. Losses narrowed to £4.6m from £5m the year before, and the firm expects to break even in the "near term", with profitability coming in the "medium term". The shares have risen by more than 150% in the last 12 months.

Be glad you didn't


Pharmaceutical firm Vernalis (Aim: VER) markets cough and cold medicine, antibiotics and migraine treatments in the US via its office in Pennsylvania, with more cough and cold products under development at its research centre in the UK. Latest interim results for the six months to

Advertisement - Article continues below

31 December showed losses rising and revenue falling. But the firm has plenty of cash and no debt. Investors have been abandoning the shares, however. The stock price is down by more than 50% in the last year.



Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Jan 2020
Investment strategy

How the fear of death affects our investment processes

Many of our investment decisions are driven by one simple fact: the knowledge that, one day, we will be dead. Here, in an extract from his new book, J…
2 Jan 2020
Share tips

Share tips: eight stocks that should deliver robust returns

Ryan Ermey of US publication Kiplinger’s Personal Finance chooses his favourite stocks for the next decade, which should be able to grow for years.
28 Dec 2019

The good investments of the 2010s – and the bad

John Stepek takes a look back on which investments did well and which did badly in the decade that’s about to come to an end.
26 Dec 2019

Most Popular

Global Economy

The MoneyWeek Podcast: James Ferguson on the virus, the lockdown, and what comes next

Merryn talks to MoneyWeek regular James Ferguson of Macrostrategy Partnership about what's happened so far with the virus; whether the lockdown was th…
28 May 2020

As full lockdown ends, what are the risks for investors?

In the UK and elsewhere, people are gradually being let off the leash as the lockdown begins to end. John Stepek looks at what risks remain for invest…
29 May 2020

Can the UK housing market escape a slump?

The Bank of England is predicting a 16% slump in house prices.
29 May 2020